Cargando…
Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort
INTRODUCTION: Intraoperative Radiotherapy (ioRT) is an emerging treatment option in oncologic surgery for various diseases including intraaxial brain lesions to improve surgical outcome and accelerate the adjuvant oncologic therapy. Despite its use in glioma surgery, the application and data regardi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826792/ https://www.ncbi.nlm.nih.gov/pubmed/36632525 http://dx.doi.org/10.3389/fsurg.2022.1071804 |
_version_ | 1784866932814512128 |
---|---|
author | Krauss, Philipp Steininger, Kathrin Motov, Stefan Sommer, Bjoern Bonk, Maximilian Niklas Cortes, Abraham Wolfert, Christina Stueben, Georg Shiban, Ehab Kahl, Klaus Henning |
author_facet | Krauss, Philipp Steininger, Kathrin Motov, Stefan Sommer, Bjoern Bonk, Maximilian Niklas Cortes, Abraham Wolfert, Christina Stueben, Georg Shiban, Ehab Kahl, Klaus Henning |
author_sort | Krauss, Philipp |
collection | PubMed |
description | INTRODUCTION: Intraoperative Radiotherapy (ioRT) is an emerging treatment option in oncologic surgery for various diseases including intraaxial brain lesions to improve surgical outcome and accelerate the adjuvant oncologic therapy. Despite its use in glioma surgery, the application and data regarding ioRT in the treatment of brain metastases (BMs) is sparse. Here were report the largest series of supratentorial BMs treated with resection and ioRT according to functional outcome and adverse events. METHODS: We performed a retrospective chart review analysis of patients undergoing surgery for BMs following an interdisciplinary tumor board decision in every case with ioRT at our institution. Patient properties, functional status (Karnofsky Performance Score/KPS) before and after surgery as well as oncologic (disease, recursive partitioning analysis, lesion size) and operative parameters were analyzed until hospital discharge. Adverse events (AE) were recorded until 30 days after surgery and rated according to the Clavien Dindo Grading (CDG) scale. RESULTS: 70 patients (40 female) with various oncologic diseases were identified and analyzed. Six underwent prior RT. Mean age was 66 ± 11 years. Preoperative median KPS was 80% with a mean BM volume of 3.2 ± 1.2 cm(3). Nine patients (13%) experienced in total 14 AEs, including 2 cases (3%) of postoperative death (CDG5) and 2 with new postoperative epilepsy necessitating additional pharmacotreatment (CDG2). Five patients suffered from new neurologic deficit (CDG1) not needing further surgical or medical treatment. After surgery, the neurological status in 7 patients (10%) deteriorated while it improved in 21 cases (30%). Patients experiencing AEs had longer hospitalization and poorer postoperative KPS mdn. 90 vs. 80%. There was no statistically significant deterioration of the functional status during the immediate postoperative course in the whole patient cohort. CONCLUSION: Surgery for supratentorial BMs with ioRT seems safe and feasible. Further studies on the benefit regarding oncologic outcome need to be performed. |
format | Online Article Text |
id | pubmed-9826792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98267922023-01-10 Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort Krauss, Philipp Steininger, Kathrin Motov, Stefan Sommer, Bjoern Bonk, Maximilian Niklas Cortes, Abraham Wolfert, Christina Stueben, Georg Shiban, Ehab Kahl, Klaus Henning Front Surg Surgery INTRODUCTION: Intraoperative Radiotherapy (ioRT) is an emerging treatment option in oncologic surgery for various diseases including intraaxial brain lesions to improve surgical outcome and accelerate the adjuvant oncologic therapy. Despite its use in glioma surgery, the application and data regarding ioRT in the treatment of brain metastases (BMs) is sparse. Here were report the largest series of supratentorial BMs treated with resection and ioRT according to functional outcome and adverse events. METHODS: We performed a retrospective chart review analysis of patients undergoing surgery for BMs following an interdisciplinary tumor board decision in every case with ioRT at our institution. Patient properties, functional status (Karnofsky Performance Score/KPS) before and after surgery as well as oncologic (disease, recursive partitioning analysis, lesion size) and operative parameters were analyzed until hospital discharge. Adverse events (AE) were recorded until 30 days after surgery and rated according to the Clavien Dindo Grading (CDG) scale. RESULTS: 70 patients (40 female) with various oncologic diseases were identified and analyzed. Six underwent prior RT. Mean age was 66 ± 11 years. Preoperative median KPS was 80% with a mean BM volume of 3.2 ± 1.2 cm(3). Nine patients (13%) experienced in total 14 AEs, including 2 cases (3%) of postoperative death (CDG5) and 2 with new postoperative epilepsy necessitating additional pharmacotreatment (CDG2). Five patients suffered from new neurologic deficit (CDG1) not needing further surgical or medical treatment. After surgery, the neurological status in 7 patients (10%) deteriorated while it improved in 21 cases (30%). Patients experiencing AEs had longer hospitalization and poorer postoperative KPS mdn. 90 vs. 80%. There was no statistically significant deterioration of the functional status during the immediate postoperative course in the whole patient cohort. CONCLUSION: Surgery for supratentorial BMs with ioRT seems safe and feasible. Further studies on the benefit regarding oncologic outcome need to be performed. Frontiers Media S.A. 2022-12-26 /pmc/articles/PMC9826792/ /pubmed/36632525 http://dx.doi.org/10.3389/fsurg.2022.1071804 Text en © 2022 Krauss, Steininger, Motov, Sommer, Bonk, Cortes, Wolfert, Stueben, Shiban and Kahl. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Krauss, Philipp Steininger, Kathrin Motov, Stefan Sommer, Bjoern Bonk, Maximilian Niklas Cortes, Abraham Wolfert, Christina Stueben, Georg Shiban, Ehab Kahl, Klaus Henning Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title | Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title_full | Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title_fullStr | Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title_full_unstemmed | Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title_short | Resection of supratentorial brain metastases with intraoperative radiotherapy. Is it safe? Analysis and experiences of a single center cohort |
title_sort | resection of supratentorial brain metastases with intraoperative radiotherapy. is it safe? analysis and experiences of a single center cohort |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826792/ https://www.ncbi.nlm.nih.gov/pubmed/36632525 http://dx.doi.org/10.3389/fsurg.2022.1071804 |
work_keys_str_mv | AT kraussphilipp resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT steiningerkathrin resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT motovstefan resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT sommerbjoern resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT bonkmaximilianniklas resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT cortesabraham resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT wolfertchristina resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT stuebengeorg resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT shibanehab resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort AT kahlklaushenning resectionofsupratentorialbrainmetastaseswithintraoperativeradiotherapyisitsafeanalysisandexperiencesofasinglecentercohort |